期刊文献+

短程干扰素α联合拉米夫定个体化长疗程递减治疗慢性乙型肝炎的临床分析

The clinical analysis of individual,long-term,top-down therapy with lamivudine combined with the short course of Interferon-α for chronic hepatitis B
下载PDF
导出
摘要 目的观察短程干扰素α联合拉米夫定个体化长疗程递减治疗慢性乙型肝炎的可行性。方法178例慢性乙型肝炎患者为研究对象,按3:1随机分组,观察组132例,对照组46例。178例中联合干扰素治疗者52例,其中观察组联合干扰素治疗38例(占28.8%),对照组14例(占30.4%);比较疗程、疗效、治疗费用和停药后反跳、复发及YMDD变异相关情况。结果拉米夫定个体化治疗最长60月,最小用量1/9片/d,减量后HBV-DNA反跳共发生28例,占21.2%,增加剂量后可有效控制病情;拉米夫定停药后反跳共发生42例,对照组11例,占23.9%;观察组31例,占23.5%;观察组YMDD变异23.5%(31/132),对照组YMDD变异23.9%(11/46);观察组HBeAg转阴率62.8%(49/78),对照组26.8%(11/41);观察组联合干扰素治疗HBeAg转阴率68.4%,高于单一拉米夫定治疗组57.5%,对照组联合干扰素治疗HBeAg转阴率42.8%,高于单一拉米夫定治疗组18.5%。观察组拉米夫定治疗费用节省2/3左右。结论拉米夫定个体化长疗程递减治疗乙型肝炎是可行的,延长用药时间且较长期控制病情,大大减轻病人的经济负担且未见减量和延长疗程诱导YMDD变异发生。 Objective To investigate the effect of individual, long-term, top-down therapy with the short course of intcrferon-α combined with lamivudine for chronic hepatitis B. Methods One hundred and seventy-eight patients with chronic hepatitis B virus infection were enrolled. The ratio of randomized grouping was 3: 1. Observation group included 132 patients and control group included 46 patients. Fifty-two patients received treatment with interferon including 38 patients (28.8%) in observation group and 14 patients (30.4%) in control group, respectively. Therapeutic course, efficacy, costs, recurrence and YMDD mutation were compared. Results Individual treatment with lamivudine was up to 60 months and the minimum dosage of 1/9 tablet every day. Recurrence of HBV-DNA occurred in 28 patients (21.2%) when extenuation. However, condition could be controlled by elevated doses. Recurrence occurred in 42 patients including 11 patients (23.9%) in control group and 31 patients (23.5%) in observation group after lamivudine administration. YMDD mutations were observerd in 23.5% (31/132) patients and 23.9% (11/46) patients in observation group and control group respectively. Furthermore, HBeAg negative rates were 62.8% (49/78) and 26.8% (11/41 ) in observation group and control group respectively. Patients in combination with interferon administration in observation group reeeived the HBeAg negative rate of 68.4% , whieh was higher than lamivudine admistration only (57.5%). Patients in combination with interferon administration in control group received the HBeAg negative rate of 42.8% , which was also higher than lamivudine admistration only ( 18.5% ). Two thirds cost of lamivudinc can be saved in observation group. Conclusion Individual, long-term, top-clown therapy with lamivudine in hepatitis B treatment is feasible, and can reduce the cost of the disease for patients. Disease can be controlled by prolonging the medication without YMDD mutaions.
出处 《胃肠病学和肝病学杂志》 CAS 2008年第11期911-913,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 乙型肝炎病毒 慢性乙型肝炎 干扰素Α 拉米夫定 YMDD变异 Hepatitis B virus Chronic hepatitis B Interferon-or Lamivudine YMDD mutation
  • 相关文献

参考文献7

二级参考文献11

  • 1江家骥,阚志超,刘家俊,郑瑞丹,杨嘉恩,陈达,杨铮.不同剂量双环醇片治疗慢性乙型肝炎疗效和安全性分析[J].传染病信息,2005,18(2):80-81. 被引量:4
  • 2Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol, 2003, 13: 255-272.
  • 3Marcellin P. Advances in therapy for chronic hepatitis B. Semin Liver Dis, 2002, 22 (Suppl 1): 33-36.
  • 4Manns MP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis, 2002, 22(Suppl 1): 7-13.
  • 5Kiyosawa K, Tanaka E. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B. J Gastroenterol, 2001, 36:139-141.
  • 6Johnson MA, Jenkins JM, Bye C. A study of pharmacokinetic interaction between lamivudine and alpha interferon. Eur J Clin Pharmacol, 2000, 56: 289-292.
  • 7Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol,2002, 17 (Suppl 3): 333-337.
  • 8Schalm S, De Man R, Janssen H. Combination and newer therapies for chronic hepatitis B. J Gastroenterol Hepatol, 2002, 17(Suppl 3):338-341.
  • 9中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14010
  • 10宋家武,林菊生,孔心涓,梁扩寰.检测拉米夫定耐药位点基因芯片的研制及其应用初探[J].中华检验医学杂志,2003,26(2):83-85. 被引量:16

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部